Dr. Celine Wilke

Chief Medical Officer of ITM

Dr. Celine Wilke joined ITM as Chief Medical Officer in April 2025 to guide ITM’s clinical programs and further accelerate the development of the company’s drug pipeline. She holds nearly 20 years of industry experience, most recently in radiopharmaceutical drug development. Her expertise in advancing precision oncology treatments from early development to regulatory approval may guide ITM’s medical team through the continued development and potential commercialization of its radiopharmaceutical candidates. 

Before joining ITM, Celine held various senior leadership positions at Novartis/ Basel, focusing on strategic drug development, including regulatory discussions and global NDA submissions, as well as functional processes. As Global Program Clinical Head for prostate cancer, she oversaw clinical trials for radiopharmaceutical therapies and imaging compounds, resulting in the approval of Pluvicto^® and Locametz^®. 

Celine holds a Doctor of Medicine from Rostock University (Germany).